Biogen Inc. BIIB
253.48 USD +4.55 (+1.83%)
Nov 4, 2026, 9:33 AM EST
252.00 Day range 254.17
149.33 52-week range 253.84
- YTD
- +44.03%
- 1 year
- +69.74%
Analyst view
Consensus: buy
Buy
Price target (mean) 264.82 +4.5% upside
Now 253.48
- Target (low)
- 175.00
- Target (mean)
- 264.82
- Target (high)
- 325.00
Ratings (0m) 36 25 buy · 10 hold · 1 sell
- Strong buy4
- Buy21
- Hold10
- Sell1
- Strong sell0
Recommendation trend
- This month 36
- 1 month ago 36
- 2 months ago 35
- 3 months ago 35
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.84 | 2.44 – 3.87 | 1.99 | +42.5% | 2.60B | +14.3% | 27 |
| Next quarter | 3.55 | 2.93 – 4.04 | 3.57 | -0.6% | 2.61B | +5.2% | 13 |
| Current year | 12.52 | 12.22 – 13.07 | 15.28 | -18.1% | 10.53B | +6.5% | 32 |
| Next year | 16.26 | 13.90 – 18.67 | 12.52 | +29.9% | 10.76B | +2.2% | 34 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Guggenheim | Maintained | Buy | Buy |
| Nov 2, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 29, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Oct 29, 2026 | Argus Research | Upgrade | Hold | Buy |
| Oct 29, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Oct 29, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Oct 29, 2026 | UBS | Maintained | Buy | Buy |
| Oct 29, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 29, 2026 | Wedbush | Maintained | Neutral | Neutral |
| Oct 29, 2026 | Truist Securities | Reiterated | Buy | Buy |
| Oct 29, 2026 | Baird | Maintained | Outperform | Outperform |
| Oct 29, 2026 | Needham | Maintained | Buy | Buy |
| Oct 28, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Oct 22, 2026 | B of A Securities | Maintained | Neutral | Neutral |
| Oct 21, 2026 | TD Cowen | Maintained | Buy | Buy |
| Oct 20, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Oct 12, 2026 | JP Morgan | Upgrade | Neutral | Overweight |
| Oct 9, 2026 | UBS | Maintained | Buy | Buy |
| Oct 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 10, 2026 | HSBC | Maintained | Reduce | Reduce |
| Sep 3, 2026 | Piper Sandler | Reiterated | Overweight | Overweight |
| Aug 25, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 13, 2026 | Wolfe Research | Upgrade | Peer Perform | Outperform |
| Aug 4, 2026 | Mizuho | Maintained | Outperform | Outperform |
| Aug 3, 2026 | Citigroup | Maintained | Neutral | Neutral |
| Jul 30, 2026 | UBS | Maintained | Buy | Buy |
| Jul 30, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Jul 30, 2026 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jul 30, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 30, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
